ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that is has signed a new contract for the use of eValuator with a 900-bed, Altera EHR-based health system serving northern Texas. This marks the fourth Texas health system to adopt eValuator, reinforcing Streamline Health’s growing presence in the region.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. eValuator’s AI-enhance pre-bill code auditing ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide while avoiding denials.
“Texas plays a pivotal role in our nation’s healthcare landscape and we are proud to expand our footprint there,” stated Ben Stilwill, Chief Executive Officer. “Our team is excited to help another of our nation’s health systems ensure they are accurately paid for the care they’ve provided.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
Last Trade: | US$3.61 |
Daily Change: | -0.26 -6.72 |
Daily Volume: | 3,327 |
Market Cap: | US$15.410M |
December 18, 2024 December 16, 2024 October 08, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load